Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$220.83-1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Intact: The reason to own it still holds.
Biogen manages a mid-single digit revenue decline in 2026. It invests in growth through acquisitions like Apellis and RayThera. Earnings per share are expected around $14.75 in 2026 and $16.63 in 2027. Profit margins remain stable with steady cash flow.
Revenue decline could worsen beyond mid-single digits. Investment in growth may not pay off due to pipeline cuts. Earnings could fall short of $14.25 to $15.25 per share in 2026. Legal and management changes may disrupt execution.
The market expects about 3% revenue growth and prices the stock roughly 26% below our valuation model's midpoint. Our view is more optimistic on earnings growth and successful integration of acquisitions.
Breaks if: FCF yield falls below 8%
Breaks if: EPS falls below $14.25 in FY26 or below $16.63 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder investment with a focus on long-term growth. The current thesis state remains intact, driven by solid revenue growth and a strategic expansion of its Growth Portfolio.
The market appears to have priced in a neutral valuation, with BIIB being seen as cheap compared to its peers. There is a slight expectations gap, indicating that some positive developments may not be fully reflected in the stock's current valuation.
Management is likely to continue delivering on sustainable revenue growth, as evidenced by recent results showing a 3% increase in revenue. However, there are mixed signals regarding the advancement of the late-stage pipeline and the integration of the Apellis Pharmaceuticals acquisition.
The thesis hinges on the performance of the Healthcare sector and the ability of BIIB to maintain or improve its guidance. Key factors include the outcomes of upcoming earnings reports from sector leaders and the company's management decisions regarding its pipeline and acquisitions.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company is expanding its growth portfolio. It is also advancing its late-stage pipeline with new data. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Significant setbacks or pipeline reductions from acquisitions
Breaks if: revenue decline exceeds 5% YoY in FY26
Biogen aims to manage a mid-single digit percentage decline in total revenue for 2026 compared to 2025.
Over the next 1 to 3 years, BIIB's performance will depend on its execution of growth strategies and sector dynamics. Not investment advice.